Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) / Roche, Halozyme - LARVOL DELTA

IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non-small-cell lung cancer and PK comparison to other approved indications. (PubMed, Ann Oncol) - P3 | "Compared with IV, atezolizumab SC demonstrated non-inferior drug exposure at Cycle 1. Efficacy, safety, and immunogenicity were similar between arms and consistent with the known profile for atezolizumab IV. Similar drug exposure and clinical outcomes following SC and IV administration support the use of atezolizumab SC as an alternative to atezolizumab IV."

Journal • Metastases • P3 data • PK/PD data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

From intravenous to subcutaneous immunotherapy: Effects on care pathways and capacity in lung cancer day hospitals (ELCC 2026) - "Modeling indicated that treating 50% of patients via SC could free 468 hours of chair time and 149 hours of nursing time annually, enabling up to 402 additional sessions without extra resources.Conclusions Subcutaneous atezolizumab significantly improves day-hospital efficiency by reducing nurse workload, chair occupancy, and patient stay. These gains translate into increased capacity without additional investment, offering a practical solution to address organizational challenges resulting from increased immunotherapy volumes. Circuit optimization could further amplify these benefits."

Clinical • Lung Cancer • Oncology • Solid Tumor

Patient-reported outcomes for atezolizumab subcutaneous and intravenous: Results from the Spanish population included in IMscin002 (ELCC 2026) - P2 | "In terms of satisfaction, pts reported higher mean scores for SC vs. IV in overall satisfaction (78.5 vs. 69.5) and convenience (84.6 vs. 72.4).Conclusions In the Spanish IMscin002 cohort, atezolizumab SC demonstrated superior patient-reported satisfaction and convenience compared to the IV formulation, while maintaining stable HRQoL. These findings confirm that switching to SC administration does not compromise patient well-being and highlight the potential of this formulation to improve patient experience in Spanish clinical practice."

Clinical • Patient reported outcomes • Lung Cancer • Non Small Cell Lung Cancer

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: University of Washington | Initiation date: Mar 2026 ➔ Jun 2026

Checkpoint inhibition • Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CXCL8 • RET • ROS1

Real-World Time, Wastage & Efficiency Impacts of Subcutaneous vs. Intravenous Atezolizumab at The Clatterbridge Cancer Centre NHS Foundation Trust (BTOG 2026) - "Subcutaneous (SC) atezolizumab shortens administration time versus the intravenous (IV) form, but the real-world impact on patient SACT unit time was unknown. This study measured the impact of the IV to SC atezolizumab changeover at CCC, measuring patient SACT unit length of stay (LoS), pharmacy drug wastage, and time from decision-to-treat (DTT) to treatment initiation."

Clinical • Real-world • Real-world evidence • Oncology

Pharmacokinetic insights into atezolizumab SC: viability of extended dosing intervals beyond the standard regimen. (PubMed, Clin Transl Oncol) - "Our PopPK model suggests that extending SC atezolizumab dosing to 4 or 5 weeks maintains therapeutic efficacy and could serve as a clinically viable alternative to standard triweekly dosing. Longer intervals may reduce efficacy and require clinical validation."

Journal • PK/PD data • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (clinicaltrials.gov) - P3 | N=336 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P3 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents. (PubMed, J Thorac Dis) - No abstract available

Checkpoint inhibition • Journal • Oncology

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=5 | Active, not recruiting | Sponsor: University of Southern California | Trial completion date: Jul 2025 ➔ Dec 2027 | Trial primary completion date: Jul 2025 ➔ Dec 2026 | Terminated ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1

Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC. (PubMed, JTO Clin Res Rep) - P2 | "There were no new safety findings, and switching between the administration routes was well tolerated. These results support the preference for SC formulations to reduce the treatment burden."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration (IASLC-WCLC 2025) - P2, P3 | "Conclusions : No new or unexpected safety findings were observed. Longer term data support that most patients prefer atezolizumab SC versus IV, and that atezolizumab SC has similar efficacy, PROs, and a similar safety profile to atezolizumab IV."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • PD-L1

Subcutaneous Immunotherapy in Cancer: Where We Are Now, What It Changes, and What to Watch Next. (PubMed, JCO Oncol Pract) - "Regulatory approvals now include SC atezolizumab and nivolumab across broad indications, SC amivantamab in Europe, and SC pembrolizumab following positive phase III results. The integration of SC immunotherapy into routine practice may improve patient experience, alleviate pressure on oncology services, and reduce health system costs without compromising outcomes. Future research should focus on implementation, real-world cost-effectiveness, and the potential for SC combinations in multiagent regimens."

Journal • Review • Oncology

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: University of Washington

Checkpoint inhibition • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • CXCL8 • RET • ROS1

IMscin002 patient population included in Spain, an analysis of patient preference and satisfaction with atezolizumab SC formulation (ESMO-IO 2025) - P2 | "Nurses also reported a reduced time in SC management in the treatment room in comparison to IV. These results are comparable with the ones reported in the full IMscin002 global cohort."

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice (clinicaltrials.gov) - P=N/A | N=700 | Recruiting | Sponsor: Hoffmann-La Roche

New trial • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • PD-L1

Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer. (PubMed, Oncol Ther) - P2 | "Most patients preferred atezolizumab SC regardless of baseline characteristics, mean injection duration, and cumulative number of SC injections. The trend for a stronger preference was higher among patients who preferred SC than those who preferred IV. Our findings suggest that the proportion of preference for atezolizumab SC over IV is highest in patients aged > 74 years, and that administrator's experience could be an important factor influencing patient preference."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • PD-L1

Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer (Springer) - "Among 179 patients randomized, demographics and characteristics were generally balanced between arms. Overall, 87/123 patients (70.7%) preferred atezolizumab SC, of whom 86.2% had a very/fairly strong preference compared with 69.2% of patients who preferred IV (n = 26/123, 21.1%). Patient preference for atezolizumab SC was independent of baseline characteristics and mean injection duration. A higher proportion of preference was seen in patients aged > 74 years (87.5%)."

P2 data • Non Small Cell Lung Cancer

Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center (ISPOR-EU 2025) - "This study demonstrates that SC atezolizumab compared to IV delivery significantly reduces CTU chair time. Further research is warranted into the potential clinical implications for increased service capacity and more efficient use of service resources."

Clinical • HEOR • Real-world • Real-world evidence • Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the NCCN Drugs & Biologics Compendium (NCCN Compendium), and the NCCN Radiation Therapy Compendium for Thymomas and Thymic Carcinomas, Version 1.2026. (NCCN)

NCCN guideline • Thymic Carcinoma • Thymoma

Jazz Pharmaceuticals...announced that the U.S. Food and Drug Administration (FDA) has granted approval for Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy... (PRNewswire) - "The FDA approval is based on results from the Phase 3 IMforte trial (NCT05091567), which showed that the Zepzelca and atezolizumab combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to atezolizumab maintenance therapy alone."

FDA approval • Small Cell Lung Cancer

India clears Roche’s 7-minute cancer injection Tecentriq for patients, with Phase IV trial condition (The Economic Times) - "Roche has received clearance to import and market Atezolizumab injection (Tecentriq) for subcutaneous administration in India, potentially reducing cancer treatment time and costs. The approval, granted by a technical committee, requires Roche to conduct a Phase IV clinical trial in India."

Approval • Alveolar Soft Tissue Sarcoma • Hepatocellular Cancer • Melanoma • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Triple Negative Breast Cancer • Urothelial Cancer

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=5 | Terminated | Sponsor: University of Southern California | N=37 ➔ 5 | Trial completion date: Dec 2026 ➔ Jul 2025 | Recruiting ➔ Terminated | Trial primary completion date: Dec 2025 ➔ Jul 2025; insufficient accrual

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), the NCCN Guidelines Navigator, and the NCCN Drugs & Biologics Compendium (NCCN Compendium), Version 4.2025. (NCCN)

dMMR • NCCN guideline • Colon Cancer • Microsatellite Instability

Decentralising delivery of systemic anti-cancer therapy (SACT) with subcutaneous atezolizumab: service challenges, opportunities and case studies. (PubMed, Br J Nurs) - No abstract available

Journal • Oncology

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis, Version 2.2025. (NCCN)

NCCN guideline • Multiple Myeloma • Oncology • Solid Tumor